Dublin, May 22, 2017 -- Research and Markets has announced the addition of the "Global Influenza Vaccine Market & Forecast (30 Countries Market & Vaccinated Population Data) By (Pediatrics & Adult) & Vaccine Brands Analysis" report to their offering.
Global Influenza Vaccine Market is worth more than US$ 5 Billion
Global Influenza Vaccine Market & Forecast (30 Countries Market & Vaccinated Population Data) By (Pediatrics & Adult) & Vaccine Brands Analysis is our 8th report on the Influenza Vaccine Market. This is a 383 page report with 386 Figures and 7 Tables provides data of 30 countries globally on Influenza Vaccine Market. The report provides data on Pediatrics and Adult Influenza Vaccinated Population Numbers and Market.
Globally Pediatrics Influenza Vaccinated Population was more than 150 Thousand, but still this figure was significantly less than the Adult Influenza Vaccinated Population. As per our research Pediatrics Influenza Vaccinated population will decline in future and Adult Influenza Vaccinated Population will increase in forecast period.
United States has the highest market share in Influenza Vaccine Market. United States Influenza Vaccine Market Share was almost 4 times more than China and Japan Influenza Vaccine Market Share. United States & China together captures close to 60 percent in Pediatrics Influenza Vaccine Market Share. Whereas, in adult vaccination segments, United States and Japan will share more than 50 percent market share by 2022.
Scope of Study:
- Influenza Vaccine Market has been divided into two segments Pediatrics Influenza Vaccine Market and Adult Influenza Vaccine Market
- Influenza Vaccine Market share & Forecast, Pediatrics Influenza Vaccine Market share & Forecast and Adult Influenza Vaccine Market share & Forecast
- Influenza Vaccinated Population & Forecast has been divided into two segments Pediatrics Influenza Vaccinated Population & Forecast and Adult Influenza Vaccinated Population & Forecast
- Influenza Vaccine Brand Sales and Forecast
All 30 Countries have been extensively studied from 2 major points, which has been further sub-divided into 2 more points:
1. Influenza Vaccine Market & Forecast (2011 - 2022)
a. Pediatrics Influenza Vaccine Market & Forecast
b. Adult Influenza Vaccine Market & Forecast
2. Influenza Vaccinated Population & Forecast (2011 - 2022)
a. Pediatrics Influenza Vaccinated Population & Forecast
b. Adult Influenza Vaccinated Population & Forecast
This report offers the best viewpoint on the leading five influenza vaccine brands:
1. Vaxigrip/Fluzone
2. Fluarix/ Flulaval
3. FluMist/Fluenz
4. Afluria/Fluvax and Fluvirin/Flucelvax
5. Anflu
This report is a combination of 6 reports:
1. Europe Influenza Vaccine Market & Forecast (23 Countries Market & Vaccinated Population Data) By (Pediatrics & Adult) & Vaccine Brands Analysis
2. Influenza Vaccine Market in Italy, Malta, Portugal and Spain (South Europe) By (Child & Adult) Forecast
3. Influenza Vaccine Market & Forecast in (West Europe) Netherlands, Germany, France, Ireland, Luxembourg, Poland and United Kingdom By (Child & Adult)
4. Nordics Seasonal Influenza Vaccine Market Forecast in (Denmark, Finland, Iceland, Norway & Sweden) By (Child & Adult) Vaccination
5. Seasonal Influenza Vaccination Market in Hungary, Romania, Slovakia and Slovenia (East Europe) By (Infant & Adult) Forecast
6. Seasonal Influenza Vaccination Market in Lithuania, Estonia, Latvia (Baltic Countries) By (Child & Adult) Forecast
Key Topics Covered:
1 Executive Summary
2 Influenza - Introduction
3 Structure of Influenza Virus
4 Notable Influenza Pandemics
5 Worldwide Influenza Vaccinated Population
6 Worldwide Seasonal Influenza Vaccine Market
7 Worldwide Seasonal Influenza Vaccine Market Share Analysis
8 United States
9 Netherlands
10 Denmark
11 Estonia
12 Finland
13 Germany
14 France
15 Hungary
16 Iceland
17 Ireland
18 Italy
19 Latvia
20 Lithuania
21 Luxembourg
22 Malta
23 Norway
24 Poland
25 Portugal
26 Romania
27 Slovakia
28 Slovenia
29 Spain
30 Sweden
31 United Kingdom
32 China
33 India
34 Brazil
35 Japan
36 Australia
37 New Zealand
38 Worldwide - Seasonal Influenza Vaccine Brand Sales and Forecast
39 Seasonal Influenza Vaccine - Growth Drivers
40 Seasonal Influenza Vaccine - Challenges
For more information about this report visit http://www.researchandmarkets.com/research/5tq8d8/global_influenza
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Vaccines, Pediatrics


Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Washington Post Publisher Will Lewis Steps Down After Layoffs
Anta Sports Expands Global Footprint With Strategic Puma Stake
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 



